Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...
Medpage Today on MSN13h
Pulled Myeloma Drug Improves Survival in TrialA significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...
SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction ...
2d
Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...
The researchers found that administering 75 grams of vitamin C three times a week doubled overall survival rates of patients ...
A bispecifics can unseat Keytruda. | BioNTech reported an 18-month overall survival rate of 69.7%, beating the cross-trial ...
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...
Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients ...
The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback